Fig. 2From: Pharmaceutical intervention for adverse events improves quality of life in patients with cancer undergoing outpatient chemotherapyComparison of median EQ-5D-5L utility values pre- and post-intervention for each adverse event. The Wilcoxon signed-rank test was used to assess differences (*P < 0.05). Pre-intervention, adverse event onset; post-intervention, after pharmaceutical interventionBack to article page